BELZUTIFAN for Phakomatosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 17 adverse event reports in the FDA FAERS database where BELZUTIFAN was used for Phakomatosis.
Most Reported Side Effects for BELZUTIFAN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Anaemia | 154 | 15.1% | 8 | 72 |
| Fatigue | 88 | 8.6% | 0 | 16 |
| Hypoxia | 85 | 8.3% | 7 | 65 |
| Diarrhoea | 42 | 4.1% | 0 | 27 |
| Death | 41 | 4.0% | 38 | 2 |
| Dyspnoea | 40 | 3.9% | 0 | 26 |
| Haemoglobin decreased | 36 | 3.5% | 0 | 6 |
| Malignant neoplasm progression | 36 | 3.5% | 10 | 11 |
| Off label use | 35 | 3.4% | 2 | 2 |
| Oxygen saturation decreased | 30 | 2.9% | 0 | 14 |
| Nausea | 28 | 2.7% | 0 | 14 |
| Product dose omission issue | 25 | 2.5% | 0 | 3 |
| Therapy interrupted | 25 | 2.5% | 0 | 11 |
| Pneumonia | 24 | 2.4% | 3 | 22 |
| No adverse event | 22 | 2.2% | 0 | 0 |
Other Indications for BELZUTIFAN
Renal cell carcinoma (291)
Clear cell renal cell carcinoma (237)
Renal cancer (186)
Von hippel-lindau disease (55)
Haemangioblastoma (28)
Product used for unknown indication (12)
Endometrial adenocarcinoma (11)
Neoplasm (10)
Hepatocellular carcinoma (7)
Adenocarcinoma pancreas (5)